{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T20:11:57Z","timestamp":1776197517713,"version":"3.50.1"},"reference-count":343,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/V007173\/1"],"award-info":[{"award-number":["MR\/V007173\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT2008339"],"award-info":[{"award-number":["GNT2008339"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome","doi-asserted-by":"publisher","award":["104079\/Z\/14\/Z"],"award-info":[{"award-number":["104079\/Z\/14\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032810","name":"Robert and Arlene Kogod Center on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032810","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.autrev.2026.104033","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:31:33Z","timestamp":1773361893000},"page":"104033","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pathogenic mechanisms of action of autoantibody-mediated central nervous system disorders targeting neuroglial surface antigens"],"prefix":"10.1016","volume":"25","author":[{"given":"Magdalena","family":"Lerch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarosh R.","family":"Irani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudarshini","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2026.104033_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.673339","article-title":"Antibody-mediated autoimmune diseases of the CNS: challenges and approaches to diagnosis and management","volume":"12","author":"Sechi","year":"2021","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0010","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ana.25131","article-title":"Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis","volume":"83","author":"Dubey","year":"2018","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104033_bb0015","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41582-023-00776-4","article-title":"Origins and immunopathogenesis of autoimmune central nervous system disorders","volume":"19","author":"Ramanathan","year":"2023","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104033_bb0020","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41582-020-0381-z","article-title":"The B cell immunobiology that underlies CNS autoantibody-mediated diseases","volume":"16","author":"Sun","year":"2020","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104033_bb0025","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.neuron.2024.12.006","article-title":"Toward curing neurological autoimmune disorders: biomarkers, immunological mechanisms, and therapeutic targets","volume":"113","author":"Segal","year":"2025","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.autrev.2026.104033_bb0030","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001014","article-title":"Updated diagnostic criteria for paraneoplastic neurologic syndromes","volume":"8","author":"Graus","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2026.104033_bb0035","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.lungcan.2017.07.026","article-title":"Autoimmune paraneoplastic syndromes associated to lung cancer: a systematic review of the literature: Part 5: neurological auto-antibodies, discussion, flow chart, conclusions","volume":"111","author":"Sculier","year":"2017","journal-title":"Lung Cancer"},{"issue":"Pt 8","key":"10.1016\/j.autrev.2026.104033_bb0040","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/brain\/awh203","article-title":"Clinical analysis of anti-Ma2-associated encephalitis","volume":"127","author":"Dalmau","year":"2004","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.autrev.2026.104033_bb0045","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.10518","article-title":"Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments","volume":"53","author":"Pittock","year":"2003","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0050","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/ana.20529","article-title":"Amphiphysin autoimmunity: paraneoplastic accompaniments","volume":"58","author":"Pittock","year":"2005","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104033_bb0055","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s12311-022-01492-3","article-title":"A systematic review on Anti-Yo\/PCA-1 antibody: beyond cerebellar ataxia in middle-aged women with gynecologic cancer","volume":"22","author":"Mendes","year":"2023","journal-title":"Cerebellum"},{"issue":"26","key":"10.1016\/j.autrev.2026.104033_bb0060","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJM199006283222604","article-title":"Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration","volume":"322","author":"Furneaux","year":"1990","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.autrev.2026.104033_bb0065","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/1531-8249(199906)45:6<805::AID-ANA18>3.0.CO;2-G","article-title":"Association of anti-Yo (type I) antibody with paraneoplastic cerebellar degeneration in the setting of transitional cell carcinoma of the bladder: detection of Yo antigen in tumor tissue and fall in antibody titers following tumor removal","volume":"45","author":"Greenlee","year":"1999","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0070","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/ana.10225","article-title":"Anti-Hu antibodies in Merkel cell carcinoma","volume":"52","author":"Greenlee","year":"2002","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104033_bb0075","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/ana.410290303","article-title":"Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer","volume":"29","author":"Luque","year":"1991","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104033_bb0080","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/WCO.0000000000001048","article-title":"Immunotherapy in autoimmune encephalitis","volume":"35","author":"Trewin","year":"2022","journal-title":"Curr Opin Neurol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104033_bb0085","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S1474-4422(23)00083-2","article-title":"Diagnostic criteria for autoimmune encephalitis: utility and pitfalls for antibody-negative disease","volume":"22","author":"Dalmau","year":"2023","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104033_bb0095","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.autrev.2026.104033_bb0100","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(19)30244-3","article-title":"An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models","volume":"18","author":"Dalmau","year":"2019","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104033_bb0105","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"},{"issue":"Pt 6","key":"10.1016\/j.autrev.2026.104033_bb0110","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/brain\/awq113","article-title":"N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes","volume":"133","author":"Irani","year":"2010","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.autrev.2026.104033_bb0320","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(08)70224-2","article-title":"Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies","volume":"7","author":"Dalmau","year":"2008","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0325","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ana.21756","article-title":"Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents","volume":"66","author":"Florance","year":"2009","journal-title":"Ann Neurol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104033_bb0330","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJMra1708712","article-title":"Antibody-mediated encephalitis","volume":"378","author":"Dalmau","year":"2018","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.autrev.2026.104033_bb0120","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1212\/WNL.0000000000003173","article-title":"Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up","volume":"87","author":"van Sonderen","year":"2016","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.autrev.2026.104033_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103074","article-title":"Contemporary advances in antibody-mediated encephalitis: anti-LGI1 and anti-Caspr2 antibody (Ab)-mediated encephalitides","volume":"21","author":"Seery","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.autrev.2026.104033_bb0140","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1093\/brain\/awy109","article-title":"Distinct HLA associations of LGI1 and CASPR2-antibody diseases","volume":"141","author":"Binks","year":"2018","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.autrev.2026.104033_bb0335","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S1474-4422(10)70137-X","article-title":"Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series","volume":"9","author":"Lai","year":"2010","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0340","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ana.24979","article-title":"Expanded phenotypes and outcomes among 256 LGI1\/CASPR2-IgG-positive patients","volume":"82","author":"Gadoth","year":"2017","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104033_bb0345","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1212\/WNL.0000000000002917","article-title":"The clinical spectrum of Caspr2 antibody\u2013associated disease","volume":"87","author":"van Sonderen","year":"2016","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.autrev.2026.104033_bb0350","doi-asserted-by":"crossref","first-page":"5413","DOI":"10.1007\/s10072-024-07604-7","article-title":"Features of the clinical course of Autoimmune Encephalitis Associated with various antibodies","volume":"45","author":"Sakharova","year":"2024","journal-title":"Neurol Sci"},{"issue":"2","key":"10.1016\/j.autrev.2026.104033_bb0355","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1212\/WNL.0b013e318224afde","article-title":"Encephalitis and antibodies to synaptic and neuronal cell surface proteins","volume":"77","author":"Lancaster","year":"2011","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.autrev.2026.104033_bb0360","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/ana.23577","article-title":"Morvan syndrome: clinical and serological observations in 29 cases","volume":"72","author":"Irani","year":"2012","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104033_bb0175","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.autrev.2026.104033_bb0180","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1007\/s00415-023-11634-0","article-title":"Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: diagnosis and differential diagnosis","volume":"270","author":"Jarius","year":"2023","journal-title":"J Neurol"},{"issue":"13","key":"10.1016\/j.autrev.2026.104033_bb0365","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1177\/1352458517731914","article-title":"Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies","volume":"24","author":"Sepulveda","year":"2018","journal-title":"Mult Scler"},{"issue":"5","key":"10.1016\/j.autrev.2026.104033_bb0370","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/archneur.65.5.629","article-title":"Aquaporin-4 autoantibodies in a paraneoplastic context","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.autrev.2026.104033_bb0375","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J Neuroinflammation"},{"issue":"2","key":"10.1016\/j.autrev.2026.104033_bb0185","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104033_bb0190","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104033_bb0380","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/acn3.52301","article-title":"Assessment of concurrent neoplasms and a paraneoplastic association in MOGAD","volume":"12","author":"Kwon","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.autrev.2026.104033_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2025.578781","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): practical recommendations for diagnosis and management","volume":"410","author":"Sechi","year":"2026","journal-title":"J Neuroimmunol"},{"issue":"16","key":"10.1016\/j.autrev.2026.104033_bb0210","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1212\/01.wnl.0000327606.50322.f0","article-title":"Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody","volume":"71","author":"Hutchinson","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2026.104033_bb0215","article-title":"Clinical features in antiglycine receptor antibody-related disease: a case report and update literature review","volume":"15","author":"Wu","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104033_bb0390","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3389\/fneur.2020.01017","article-title":"Progressive encephalomyelitis with rigidity and myoclonus with thymoma: a case report and literature review","volume":"11","author":"Su","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.autrev.2026.104033_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577804","article-title":"Comparison of the clinical syndromes of anti-GABAa versus anti-GABAb associated autoimmune encephalitis: a systematic review","volume":"363","author":"Ronchi","year":"2022","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2026.104033_bb0235","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3389\/fneur.2020.00403","article-title":"Clinical characteristics of anti-GABA-B receptor encephalitis","volume":"11","author":"Zhu","year":"2020","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0395","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/epi.18654","article-title":"Anti-gamma-aminobutyric acid B receptor autoimmune encephalitis: clinical presentation and diagnostic insights","volume":"67","author":"Paramasivan","year":"2026","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.autrev.2026.104033_bb0245","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ana.21589","article-title":"AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location","volume":"65","author":"Lai","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2026.104033_bb0250","article-title":"Anti-Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic acid receptor encephalitis: a review","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104033_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.578012","article-title":"AMPAR autoimmunity: neurological and oncological accompaniments and co-existing neural autoantibodies","volume":"375","author":"McCombe","year":"2023","journal-title":"J Neuroimmunol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104033_bb0400","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200453","article-title":"Clinical characterization and long-term outcome in children and adults with anti-AMPA receptor encephalitis","volume":"12","author":"Milano","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"14","key":"10.1016\/j.autrev.2026.104033_bb0265","doi-asserted-by":"crossref","first-page":"7956","DOI":"10.3390\/ijms25147956","article-title":"IgLON5-IgG: innocent bystander or perpetrator?","volume":"25","author":"Andersen","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.autrev.2026.104033_bb0270","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/brain\/awac090","article-title":"Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease","volume":"146","author":"Gruter","year":"2023","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0405","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1186\/s12883-024-03984-7","article-title":"Case report: anti-IgLON5 disease combined with paraneoplastic cerebellar degeneration with the detection of anti-sulfatide IgG antibody, masquerading as meningoencephalitis","volume":"24","author":"Zhuang","year":"2024","journal-title":"BMC Neurol"},{"issue":"18","key":"10.1016\/j.autrev.2026.104033_bb0410","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/WNL.0000000000003887","article-title":"Clinical manifestations of the anti-IgLON5 disease","volume":"88","author":"Gaig","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.autrev.2026.104033_bb0280","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200350","article-title":"Clinical and paraclinical characterizations, management, and prognosis in DPPX antibody-associated encephalitis: a systematic review","volume":"12","author":"Li","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0415","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12883-022-02649-7","article-title":"Clinical and imaging analysis to evaluate the response of patients with anti-DPPX encephalitis to immunotherapy","volume":"22","author":"Xiao","year":"2022","journal-title":"BMC Neurol"},{"issue":"Pt 11","key":"10.1016\/j.autrev.2026.104033_bb0290","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1093\/brain\/aws256","article-title":"Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders","volume":"135","author":"Dale","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2026.104033_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2024.103910","article-title":"Late-onset paraneoplastic encephalitis originates from dopamine 2 receptor autoimmunity associated with prostate adenocarcinoma","volume":"93","author":"Cai","year":"2024","journal-title":"Asian J Psychiatr"},{"key":"10.1016\/j.autrev.2026.104033_bb0305","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1142160","article-title":"Anti-mGluR1 encephalitis: case illustration and systematic review","volume":"14","author":"Khojah","year":"2023","journal-title":"Front Neurol"},{"key":"10.1016\/j.autrev.2026.104033_bb0310","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2147\/ITT.S514617","article-title":"A case series of anti-metabotropic glutamate receptor 2 antibody-related diseases with distinct neurological involvement","volume":"14","author":"Zhang","year":"2025","journal-title":"Immunotargets Ther"},{"issue":"8","key":"10.1016\/j.autrev.2026.104033_bb0315","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/acn3.51831","article-title":"Clinical features and brain MRI volumetric changes in anti-mGluR5 encephalitis","volume":"10","author":"Sun","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.autrev.2026.104033_bb0425","article-title":"Autoimmune encephalitis with mGluR5 antibodies: a case series from China and review of the literature","volume":"14","author":"Guo","year":"2023","journal-title":"Front Immunol"},{"issue":"22","key":"10.1016\/j.autrev.2026.104033_bb0430","doi-asserted-by":"crossref","first-page":"e3012","DOI":"10.1212\/WNL.0000000000010854","article-title":"Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis","volume":"95","author":"Spatola","year":"2020","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.autrev.2026.104033_bb0435","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000658","article-title":"Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2","volume":"7","author":"Ruiz-Garcia","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2026.104033_bb0440","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2147\/ITT.S498345","article-title":"Anti-GluK2 encephalitis in an asian child: a case report and literature review","volume":"13","author":"Chen","year":"2024","journal-title":"Immunotargets Ther"},{"issue":"6","key":"10.1016\/j.autrev.2026.104033_bb0445","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s12311-021-01346-4","article-title":"Anti-Tr\/DNER antibody-associated cerebellar ataxia: a systematic review","volume":"21","author":"Campana","year":"2022","journal-title":"Cerebellum"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0450","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10072-022-06389-x","article-title":"Anti-Tr\/DNER antibody-associated cerebellar ataxia: three rare cases report and literature review","volume":"44","author":"Cai","year":"2023","journal-title":"Neurol Sci"},{"issue":"5","key":"10.1016\/j.autrev.2026.104033_bb0455","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200018","article-title":"Cerebellar ataxia with anti-DNER antibodies: outcomes and immunologic features","volume":"9","author":"Peter","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.autrev.2026.104033_bb0460","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200359","article-title":"Conformational antibodies to proteolipid protein-1 and its peripheral isoform DM20 in patients with CNS autoimmune demyelinating disorders","volume":"12","author":"Masciocchi","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"10.1016\/j.autrev.2026.104033_bb0465","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/ana.26017","article-title":"Ca(V) alpha2delta autoimmune encephalitis: a novel antibody and its characteristics","volume":"89","author":"Lee","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2026.104033_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2025.578550","article-title":"Pediatric anti-CaValpha2delta autoimmune encephalitis: a case report and literature review","volume":"401","author":"Zhang","year":"2025","journal-title":"J Neuroimmunol"},{"issue":"24","key":"10.1016\/j.autrev.2026.104033_bb0475","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1212\/WNL.0000000000002775","article-title":"Human neurexin-3alpha antibodies associate with encephalitis and alter synapse development","volume":"86","author":"Gresa-Arribas","year":"2016","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.autrev.2026.104033_bb0480","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s00259-022-06054-7","article-title":"Neurexin-3alpha-associated autoimmune encephalitis with intracranial diffuse large B lymphoma diagnosed on FDG and TSPO PET\/MRI","volume":"50","author":"Zhang","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.autrev.2026.104033_bb0485","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3390\/brainsci11060673","article-title":"Mild amnestic cognitive impairment and depressive symptoms in autoimmune encephalitis associated with serum anti-Neurexin-3alpha autoantibodies","volume":"11","author":"Hansen","year":"2021","journal-title":"Brain Sci"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0490","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s42466-022-00218-4","article-title":"Anti-SEZ6L2 antibodies in paraneoplastic cerebellar syndrome: case report and review of the literature","volume":"4","author":"Kather","year":"2022","journal-title":"Neurol Res Pract"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0495","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s00415-013-7134-5","article-title":"Identification of anti-Sez6l2 antibody in a patient with cerebellar ataxia and retinopathy","volume":"261","author":"Yaguchi","year":"2014","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104033_bb0500","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1007\/s00415-018-8785-z","article-title":"Anti-Sez6l2 antibody detected in a patient with immune-mediated cerebellar ataxia inhibits complex formation of GluR1 and Sez6l2","volume":"265","author":"Yaguchi","year":"2018","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0505","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12974-017-0900-z","article-title":"Identification of the flotillin-1\/2 heterocomplex as a target of autoantibodies in bona fide multiple sclerosis","volume":"14","author":"Hahn","year":"2017","journal-title":"J Neuroinflammation"},{"issue":"2","key":"10.1016\/j.autrev.2026.104033_bb0510","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcad109","article-title":"Antibodies against the flotillin-1\/2 complex in patients with multiple sclerosis","volume":"5","author":"Lleixa","year":"2023","journal-title":"Brain Commun"},{"key":"10.1016\/j.autrev.2026.104033_bb0515","article-title":"Case report: anti-flotillin 1\/2 autoantibody-associated atypical dementia","volume":"12","author":"Hansen","year":"2021","journal-title":"Front Psych"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0520","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1212\/CPJ.0000000000000741","article-title":"Limbic encephalitis with positivity for anti-flotillin antibodies in serum and CSF","volume":"11","author":"Videira","year":"2021","journal-title":"Neurol Clin Pract"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0090","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/ana.21050","article-title":"Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma","volume":"61","author":"Dalmau","year":"2007","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bib1711","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2215-0366(25)00305-0","article-title":"The distinctive psychopathology of NMDAR-antibody encephalitis compared with primary psychoses: an international, multicentre, retrospective phenotypic analysis","volume":"13","author":"Al-Diwani","year":"2026","journal-title":"Lancet Psychiatry"},{"issue":"9","key":"10.1016\/j.autrev.2026.104033_bb0115","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1093\/brain\/awq213","article-title":"Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan\u2019s syndrome and acquired neuromyotonia","volume":"133","author":"Irani","year":"2010","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.autrev.2026.104033_bb0125","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200151","article-title":"Autoimmune encephalitis criteria in clinical practice","volume":"13","author":"Orozco","year":"2023","journal-title":"Neurol Clin Pract"},{"issue":"6","key":"10.1016\/j.autrev.2026.104033_bb0130","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200318","article-title":"Autoimmune encephalitis and paraneoplastic neurologic syndromes: a nationwide study on epidemiology and antibody testing performance","volume":"11","author":"Kerstens","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"10.1016\/j.autrev.2026.104033_bb0145","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/jamaneurol.2024.0126","article-title":"Magnetic resonance imaging characteristics of LGI1-antibody and CASPR2-antibody encephalitis","volume":"81","author":"Kelly","year":"2024","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104033_bb0150","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ana.26189","article-title":"Leucine-rich Glioma-Inactivated 1 versus contactin-associated protein-like 2 antibody neuropathic pain: clinical and biological comparisons","volume":"90","author":"Ramanathan","year":"2021","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104033_bb0155","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/ana.27177","article-title":"Immunotherapy-resistant neuropathic pain and fatigue predict quality-of-life in contactin-associated protein-like 2 antibody disease","volume":"97","author":"Ceronie","year":"2025","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104033_bb0160","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/cells8020090","article-title":"Aquaporin-4 water channel in the brain and its implication for health and disease","volume":"8","author":"Mader","year":"2019","journal-title":"Cells"},{"issue":"9451","key":"10.1016\/j.autrev.2026.104033_bb0165","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.autrev.2026.104033_bb0170","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103693","article-title":"MOGAD: A comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally","volume":"24","author":"Trewin","year":"2025","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.autrev.2026.104033_bb0200","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000040","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis","volume":"1","author":"Ramanathan","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"10.1016\/j.autrev.2026.104033_bb0205","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1352458515593406","article-title":"Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis","volume":"22","author":"Ramanathan","year":"2016","journal-title":"Mult Scler"},{"issue":"8050","key":"10.1016\/j.autrev.2026.104033_bb0220","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41586-024-08454-1","article-title":"Resolving native GABA(A) receptor structures from the human brain","volume":"638","author":"Zhou","year":"2025","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.autrev.2026.104033_bb0230","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2183\/pjab.94.026","article-title":"Diversity of structure and function of GABAB receptors: a complexity of GABAB-mediated signaling","volume":"94","author":"Terunuma","year":"2018","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"issue":"24","key":"10.1016\/j.autrev.2026.104033_bb0240","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1212\/WNL.0000000000001693","article-title":"Anti-AMPA receptor encephalitis: the family of glutamatergic autoencephalitides further expands","volume":"84","author":"Panzer","year":"2015","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.autrev.2026.104033_bb0260","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.4103\/1673-5374.355742","article-title":"Anti-IgLON5 disease: a novel topic beyond neuroimmunology","volume":"18","author":"Zhang","year":"2023","journal-title":"Neural Regen Res"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0275","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/ana.23756","article-title":"Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels","volume":"73","author":"Boronat","year":"2013","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0285","doi-asserted-by":"crossref","first-page":"6442","DOI":"10.1038\/s41467-020-20221-0","article-title":"Structure of the dopamine D(2) receptor in complex with the antipsychotic drug spiperone","volume":"11","author":"Im","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0295","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1186\/s12883-024-03893-9","article-title":"Anti-dopamine receptor 2 antibody encephalitis in adults: a case report","volume":"24","author":"Wu","year":"2024","journal-title":"BMC Neurol"},{"key":"10.1016\/j.autrev.2026.104033_bb0300","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev.pharmtox.011008.145533","article-title":"Metabotropic glutamate receptors: physiology, pharmacology, and disease","volume":"50","author":"Niswender","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"46","key":"10.1016\/j.autrev.2026.104033_bb0675","doi-asserted-by":"crossref","first-page":"18161","DOI":"10.1523\/JNEUROSCI.3506-13.2013","article-title":"Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors","volume":"33","author":"Ohkawa","year":"2013","journal-title":"J Neurosci"},{"issue":"3","key":"10.1016\/j.autrev.2026.104033_bb0680","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/ana.25666","article-title":"Human cerebrospinal fluid monoclonal LGI1 autoantibodies increase neuronal excitability","volume":"87","author":"Kornau","year":"2020","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104033_bb0685","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/brain\/awaa104","article-title":"Distinctive binding properties of human monoclonal LGI1 autoantibodies determine pathogenic mechanisms","volume":"143","author":"Ramberger","year":"2020","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.autrev.2026.104033_bb0690","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200096","article-title":"Comparative effects of domain-specific human monoclonal antibodies against LGI1 on neuronal excitability","volume":"10","author":"Sell","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"10.1016\/j.autrev.2026.104033_bb0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114186","article-title":"Activity-driven synaptic translocation of LGI1 controls excitatory neurotransmission","volume":"43","author":"Cuhadar","year":"2024","journal-title":"Cell Rep"},{"key":"10.1016\/j.autrev.2026.104033_bb0705","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.bbi.2025.02.019","article-title":"Patient-derived monoclonal LGI1 autoantibodies elicit seizures, behavioral changes and brain MRI abnormalities in rodent models","volume":"126","author":"Upadhya","year":"2025","journal-title":"Brain Behav Immun"},{"issue":"11","key":"10.1016\/j.autrev.2026.104033_bb0710","first-page":"3144","article-title":"LGI1 antibodies alter Kv1.1 and AMPA receptors changing synaptic excitability, plasticity and memory","volume":"141","author":"Petit-Pedrol","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2026.104033_bb0715","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1268986","article-title":"Antibody induced seizure susceptibility and impaired cognitive performance in a passive transfer rat model of autoimmune encephalitis","volume":"14","author":"Piskin","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104033_bb0720","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0267-22.2023","article-title":"In vivo injection of anti-LGI1 antibodies into the rodent M1 cortex and hippocampus is ineffective in inducing seizures","volume":"10","author":"Baudin","year":"2023","journal-title":"eNeuro"},{"issue":"11","key":"10.1016\/j.autrev.2026.104033_bb0730","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/acn3.50919","article-title":"Hippocampal epileptogenesis in autoimmune encephalitis","volume":"6","author":"Romoli","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"issue":"17","key":"10.1016\/j.autrev.2026.104033_bb0735","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.3390\/cells11172713","article-title":"An epitope-specific LGI1-autoantibody enhances neuronal excitability by modulating Kv1.1 channel","volume":"11","author":"Extremet","year":"2022","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.autrev.2026.104033_bb0740","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/cells12020282","article-title":"Antibody properties associate with clinical phenotype in LGI1 encephalitis","volume":"12","author":"Ludewig","year":"2023","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.autrev.2026.104033_bb0530","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41594-024-01387-3","article-title":"Structural basis for antibody-mediated NMDA receptor clustering and endocytosis in autoimmune encephalitis","volume":"31","author":"Wang","year":"2024","journal-title":"Nat Struct Mol Biol"},{"issue":"11","key":"10.1016\/j.autrev.2026.104033_bb0535","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/acn3.444","article-title":"NMDAR encephalitis: passive transfer from man to mouse by a recombinant antibody","volume":"4","author":"Malviya","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"issue":"Pt 5","key":"10.1016\/j.autrev.2026.104033_bb0550","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1093\/brain\/aws092","article-title":"Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis","volume":"135","author":"Mikasova","year":"2012","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.autrev.2026.104033_bb0555","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1093\/brain\/awae163","article-title":"NMDA receptor autoantibodies primarily impair the extrasynaptic compartment","volume":"147","author":"Jamet","year":"2024","journal-title":"Brain"},{"issue":"13","key":"10.1016\/j.autrev.2026.104033_bb0565","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1016\/j.celrep.2018.05.096","article-title":"NMDA receptor autoantibodies in autoimmune encephalitis cause a subunit-specific nanoscale redistribution of NMDA receptors","volume":"23","author":"Lad\u00e9p\u00eache","year":"2018","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0570","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/ana.24195","article-title":"Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis","volume":"76","author":"Moscato","year":"2014","journal-title":"Ann Neurol"},{"issue":"17","key":"10.1016\/j.autrev.2026.104033_bb0575","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1523\/JNEUROSCI.0167-10.2010","article-title":"Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis","volume":"30","author":"Hughes","year":"2010","journal-title":"J Neurosci"},{"issue":"12","key":"10.1016\/j.autrev.2026.104033_bb0580","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/mp.2016.125","article-title":"All naturally occurring autoantibodies against the NMDA receptor subunit NR1 have pathogenic potential irrespective of epitope and immunoglobulin class","volume":"22","author":"Castillo-Gomez","year":"2017","journal-title":"Mol Psychiatry"},{"issue":"8","key":"10.1016\/j.autrev.2026.104033_bb0585","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/glia.24369","article-title":"Microglia actively remove NR1 autoantibody-bound NMDA receptors and associated post-synaptic proteins in neuron microglia co-cultures","volume":"71","author":"Rahman","year":"2023","journal-title":"Glia"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0590","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3390\/ijms24010248","article-title":"Myelinating co-culture as a model to study anti-NMDAR neurotoxicity","volume":"24","author":"Sabet","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.autrev.2026.104033_bb0595","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/ana.25699","article-title":"N-Methyl-D-aspartate receptor antibodies in autoimmune encephalopathy alter oligodendrocyte function","volume":"87","author":"Matute","year":"2020","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0605","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/s42003-021-02635-8","article-title":"Multimodal electrophysiological analyses reveal that reduced synaptic excitatory neurotransmission underlies seizures in a model of NMDAR antibody-mediated encephalitis","volume":"4","author":"Wright","year":"2021","journal-title":"Commun Biol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104033_bb0610","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/ana.24721","article-title":"Ephrin-B2 prevents N-methyl-D-aspartate receptor antibody effects on memory and neuroplasticity","volume":"80","author":"Planaguma","year":"2016","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104033_bb0615","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/epi.14662","article-title":"A mouse model of seizures in anti-N-methyl-d-aspartate receptor encephalitis","volume":"60","author":"Taraschenko","year":"2019","journal-title":"Epilepsia"},{"issue":"12","key":"10.1016\/j.autrev.2026.104033_bb0620","doi-asserted-by":"crossref","first-page":"7746","DOI":"10.1038\/s41380-021-01238-3","article-title":"Autoantibodies against NMDA receptor 1 modify rather than cause encephalitis","volume":"26","author":"Wilke","year":"2021","journal-title":"Mol Psychiatry"},{"issue":"10","key":"10.1016\/j.autrev.2026.104033_bb0625","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/s41380-017-0011-3","article-title":"Uncoupling the widespread occurrence of anti-NMDAR1 autoantibodies from neuropsychiatric disease in a novel autoimmune model","volume":"24","author":"Pan","year":"2019","journal-title":"Mol Psychiatry"},{"issue":"6","key":"10.1016\/j.autrev.2026.104033_bb0630","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1093\/brain\/awae410","article-title":"Neuro-immunobiology and treatment assessment in a mouse model of anti-NMDAR encephalitis","volume":"148","author":"Maudes","year":"2025","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.autrev.2026.104033_bb0635","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1093\/brain\/awaa250","article-title":"Autoimmune encephalitis mediated by B-cell response against N-methyl-d-aspartate receptor","volume":"143","author":"Wagnon","year":"2020","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0640","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12974-023-02844-4","article-title":"Transfer of patient\u2019s peripheral blood mononuclear cells (PBMCs) disrupts blood-brain barrier and induces anti-NMDAR encephalitis: a study of novel humanized PBMC mouse model","volume":"20","author":"Shu","year":"2023","journal-title":"J Neuroinflammation"},{"issue":"500","key":"10.1016\/j.autrev.2026.104033_bb0645","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw0044","article-title":"Autoimmune receptor encephalitis in mice induced by active immunization with conformationally stabilized holoreceptors","volume":"11","author":"Jones","year":"2019","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0650","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000915","article-title":"Placental transfer of NMDAR antibodies causes reversible alterations in mice","volume":"8","author":"Garcia-Serra","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"10","key":"10.1016\/j.autrev.2026.104033_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113166","article-title":"Human NMDAR autoantibodies disrupt excitatory-inhibitory balance, leading to hippocampal network hypersynchrony","volume":"42","author":"Ceanga","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.autrev.2026.104033_bb0660","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fnsyn.2018.00026","article-title":"Differentially altered NMDAR dependent and independent long-term potentiation in the CA3 subfield in a model of anti-NMDAR encephalitis","volume":"10","author":"Blome","year":"2018","journal-title":"Front Synaptic Neurosci"},{"key":"10.1016\/j.autrev.2026.104033_bb0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.05.012","article-title":"Impact of anti-CASPR2 autoantibodies from patients with autoimmune encephalitis on CASPR2\/TAG-1 interaction and Kv1 expression","volume":"103","author":"Saint-Martin","year":"2019","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0750","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ana.25120","article-title":"Mechanisms of Caspr2 antibodies in autoimmune encephalitis and neuromyotonia","volume":"83","author":"Patterson","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2026.104033_bb0755","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bbi.2024.08.027","article-title":"Human cerebrospinal fluid monoclonal CASPR2 autoantibodies induce changes in electrophysiology, functional MRI, and behavior in rodent models","volume":"122","author":"van Hoof","year":"2024","journal-title":"Brain Behav Immun"},{"issue":"6","key":"10.1016\/j.autrev.2026.104033_bb0765","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ana.26345","article-title":"Human CASPR2 antibodies reversibly alter memory and the CASPR2 protein complex","volume":"91","author":"Joubert","year":"2022","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1016\/j.autrev.2026.104033_bb0770","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1093\/brain\/awz119","article-title":"Behaviour and neuropathology in mice injected with human contactin-associated protein 2 antibodies","volume":"142","author":"Giannoccaro","year":"2019","journal-title":"Brain"},{"issue":"16","key":"10.1016\/j.autrev.2026.104033_bb0775","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adr9986","article-title":"Permissive central tolerance plus defective peripheral checkpoints license pathogenic memory B cells in CASPR2-antibody encephalitis","volume":"11","author":"Sun","year":"2025","journal-title":"Sci Adv"},{"issue":"12","key":"10.1016\/j.autrev.2026.104033_bb0780","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1093\/cercor\/bhz032","article-title":"Disrupted AMPA receptor function upon genetic- or antibody-mediated loss of autism-associated CASPR2","volume":"29","author":"Fernandes","year":"2019","journal-title":"Cereb Cortex"},{"key":"10.1016\/j.autrev.2026.104033_bb0785","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaut.2018.09.012","article-title":"Structural mapping of hot spots within human CASPR2 discoidin domain for autoantibody recognition","volume":"96","author":"Liang","year":"2019","journal-title":"J Autoimmun"},{"issue":"9","key":"10.1016\/j.autrev.2026.104033_bb0790","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/jamaneurol.2016.1585","article-title":"Characterization of a subtype of autoimmune encephalitis with anti-contactin-associated protein-like 2 antibodies in the cerebrospinal fluid, prominent limbic symptoms, and seizures","volume":"73","author":"Joubert","year":"2016","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104033_bb0795","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000127","article-title":"Caspr2 autoantibodies target multiple epitopes","volume":"2","author":"Olsen","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.autrev.2026.104033_bb0800","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.09.004","article-title":"Humoral signatures of Caspr2-antibody spectrum disorder track with clinical phenotypes and outcomes","volume":"6","author":"Terroba-Navajas","year":"2025","journal-title":"Med"},{"issue":"4","key":"10.1016\/j.autrev.2026.104033_bb0805","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.neuron.2018.01.033","article-title":"Immune or genetic-mediated disruption of CASPR2 causes pain hypersensitivity due to enhanced primary afferent excitability","volume":"97","author":"Dawes","year":"2018","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.autrev.2026.104033_bb0810","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00401-017-1751-5","article-title":"Persistent microglial activation and synaptic loss with behavioral abnormalities in mouse offspring exposed to CASPR2-antibodies in utero","volume":"134","author":"Coutinho","year":"2017","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.autrev.2026.104033_bb0815","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fnsyn.2020.00013","article-title":"Stereotactically injected Kv1.2 and CASPR2 antisera cause differential effects on CA1 synaptic and cellular excitability, but both enhance the vulnerability to pro-epileptic conditions","volume":"12","author":"Kirschstein","year":"2020","journal-title":"Front Synaptic Neurosci"},{"issue":"24","key":"10.1016\/j.autrev.2026.104033_bb0825","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","article-title":"Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica","volume":"69","author":"Hinson","year":"2007","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.autrev.2026.104033_bb0835","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ana.21802","article-title":"Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica","volume":"66","author":"Bennett","year":"2009","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0840","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200059","article-title":"More efficient complement activation by anti-aquaporin-4 compared with anti-myelin oligodendrocyte glycoprotein antibodies","volume":"10","author":"Lerch","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"17","key":"10.1016\/j.autrev.2026.104033_bb0845","doi-asserted-by":"crossref","first-page":"13829","DOI":"10.1074\/jbc.M112.344325","article-title":"Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays","volume":"287","author":"Phuan","year":"2012","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.autrev.2026.104033_bb0850","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1172\/JCI122942","article-title":"Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica","volume":"129","author":"Soltys","year":"2019","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.autrev.2026.104033_bb0855","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1084\/jem.20081241","article-title":"Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2","volume":"205","author":"Hinson","year":"2008","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0860","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-01294-3","article-title":"Cytoprotective IgG antibodies in sera from a subset of patients with AQP4-IgG seropositive neuromyelitis optica spectrum disorder","volume":"11","author":"Tradtrantip","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0865","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40478-019-0707-5","article-title":"AQP4ex is crucial for the anchoring of AQP4 at the astrocyte end-feet and for neuromyelitis optica antibody binding","volume":"7","author":"Palazzo","year":"2019","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"10.1016\/j.autrev.2026.104033_bb0870","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1073\/pnas.1109980108","article-title":"Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes","volume":"109","author":"Hinson","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"10.1016\/j.autrev.2026.104033_bb0880","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1073\/pnas.1701960114","article-title":"Autoantibody-induced internalization of CNS AQP4 water channel and EAAT2 glutamate transporter requires astrocytic Fc receptor","volume":"114","author":"Hinson","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"52","key":"10.1016\/j.autrev.2026.104033_bb0885","doi-asserted-by":"crossref","first-page":"45156","DOI":"10.1074\/jbc.M111.297275","article-title":"Evidence against cellular internalization in vivo of NMO-IgG, aquaporin-4, and excitatory amino acid transporter 2 in neuromyelitis optica","volume":"286","author":"Ratelade","year":"2011","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.autrev.2026.104033_bb0890","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1093\/brain\/awq177","article-title":"Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury","volume":"133","author":"Marignier","year":"2010","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0915","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000311","article-title":"Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro","volume":"4","author":"Takeshita","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2026.104033_bb0920","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118217","article-title":"Effect of NMO-IgG on the interleukin-6 cascade in astrocytes via activation of the JAK\/STAT3 signaling pathway","volume":"258","author":"Du","year":"2020","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0925","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/ana.26650","article-title":"Astrocyte-derived exosomes contribute to pathologies of neuromyelitis optica spectrum disorder in rodent model","volume":"94","author":"Xie","year":"2023","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104033_bb0935","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/ana.24630","article-title":"In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis optica-related pathology","volume":"79","author":"Herwerth","year":"2016","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104033_bb0940","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/brain\/awac079","article-title":"A new form of axonal pathology in a spinal model of neuromyelitis optica","volume":"145","author":"Herwerth","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2026.104033_bb0945","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.703249","article-title":"An experimental model of neuromyelitis optica spectrum disorder-optic neuritis: insights into disease mechanisms","volume":"12","author":"Soerensen","year":"2021","journal-title":"Front Neurol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104033_bb0950","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.21837","article-title":"Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo","volume":"66","author":"Bradl","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2026.104033_bb0955","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s40478-015-0259-2","article-title":"Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody","volume":"3","author":"Kurosawa","year":"2015","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.autrev.2026.104033_bb0960","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.msard.2019.02.025","article-title":"Repetitive intrathecal injection of human NMO-IgG with complement exacerbates disease severity with NMO pathology in experimental allergic encephalomyelitis mice","volume":"30","author":"Lee","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"10.1016\/j.autrev.2026.104033_bb0965","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00401-015-1501-5","article-title":"Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS","volume":"130","author":"Zeka","year":"2015","journal-title":"Acta Neuropathol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104033_bb0970","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00401-013-1172-z","article-title":"Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica","volume":"126","author":"Ratelade","year":"2013","journal-title":"Acta Neuropathol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104033_bb0975","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00401-013-1204-8","article-title":"Unique neuromyelitis optica pathology produced in naive rats by intracerebral administration of NMO-IgG","volume":"127","author":"Asavapanumas","year":"2014","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0980","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bbrc.2010.02.157","article-title":"Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells","volume":"394","author":"Kinoshita","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.autrev.2026.104033_bb0985","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00401-018-1950-8","article-title":"Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat","volume":"137","author":"Hillebrand","year":"2019","journal-title":"Acta Neuropathol"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2026.104033_bb0990","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jneuroim.2012.02.001","article-title":"Aquaporin-4 autoantibodies cause asymptomatic aquaporin-4 loss and activate astrocytes in mouse","volume":"245","author":"Chan","year":"2012","journal-title":"J Neuroimmunol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104033_bb0995","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/ana.22551","article-title":"Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms","volume":"70","author":"Zhang","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2026.104033_bb1035","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders","volume":"8","author":"Mader","year":"2011","journal-title":"J Neuroinflammation"},{"issue":"2","key":"10.1016\/j.autrev.2026.104033_bb1000","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1046\/j.1471-4159.1994.62020777.x","article-title":"Antibodies to myelin\/oligodendrocyte-specific protein and myelin\/oligodendrocyte glycoprotein signal distinct changes in the organization of cultured oligodendroglial membrane sheets","volume":"62","author":"Dyer","year":"1994","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb1005","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000012","article-title":"Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton","volume":"1","author":"Dale","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"13","key":"10.1016\/j.autrev.2026.104033_bb1010","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1523\/JNEUROSCI.23-13-05461.2003","article-title":"Antibody cross-linking of myelin oligodendrocyte glycoprotein leads to its rapid repartitioning into detergent-insoluble fractions, and altered protein phosphorylation and cell morphology","volume":"23","author":"Marta","year":"2003","journal-title":"J Neurosci"},{"issue":"39","key":"10.1016\/j.autrev.2026.104033_bb1015","doi-asserted-by":"crossref","first-page":"13992","DOI":"10.1073\/pnas.0504979102","article-title":"Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology","volume":"102","author":"Marta","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.autrev.2026.104033_bb1020","doi-asserted-by":"crossref","first-page":"8985","DOI":"10.1074\/jbc.M413174200","article-title":"Signaling cascades activated upon antibody cross-linking of myelin oligodendrocyte glycoprotein: potential implications for multiple sclerosis","volume":"280","author":"Marta","year":"2005","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.autrev.2026.104033_bb1025","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/ana.21916","article-title":"Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease","volume":"66","author":"Brilot","year":"2009","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb1030","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00401-016-1559-8","article-title":"Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen","volume":"132","author":"Kinzel","year":"2016","journal-title":"Acta Neuropathol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104033_bb1050","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s12264-019-00375-8","article-title":"Myelin oligodendrocyte Glycoprotein-IgG contributes to oligodendrocytopathy in the presence of complement, distinct from astrocytopathy induced by AQP4-IgG","volume":"35","author":"Fang","year":"2019","journal-title":"Neurosci Bull"},{"key":"10.1016\/j.autrev.2026.104033_bb1055","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1014071","article-title":"Complement-dependent cytotoxicity of human autoantibodies against myelin oligodendrocyte glycoprotein","volume":"17","author":"Kohyama","year":"2023","journal-title":"Front Neurosci"},{"issue":"2","key":"10.1016\/j.autrev.2026.104033_bb1060","article-title":"Humoral signatures of MOG-antibody-associated disease track with age and disease activity","volume":"4","author":"Spatola","year":"2023","journal-title":"Cell Rep Med"},{"issue":"2","key":"10.1016\/j.autrev.2026.104033_bb1095","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ana.25291","article-title":"Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein","volume":"84","author":"Spadaro","year":"2018","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb1100","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12974-017-0984-5","article-title":"Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination","volume":"14","author":"Peschl","year":"2017","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.autrev.2026.104033_bb1105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/2051-5960-2-35","article-title":"Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain","volume":"2","author":"Saadoun","year":"2014","journal-title":"Acta Neuropathol Commun"},{"issue":"13","key":"10.1016\/j.autrev.2026.104033_bb1110","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2300648120","article-title":"Dissection of complement and Fc-receptor-mediated pathomechanisms of autoantibodies to myelin oligodendrocyte glycoprotein","volume":"120","author":"Mader","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb1115","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12974-019-1637-7","article-title":"Anti-MOG autoantibodies pathogenicity in children and macaques demyelinating diseases","volume":"16","author":"Serguera","year":"2019","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.autrev.2026.104033_bb1120","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12974-015-0378-5","article-title":"Immune profile of an atypical EAE model in marmoset monkeys immunized with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund\u2019s adjuvant","volume":"12","author":"Jagessar","year":"2015","journal-title":"J Neuroinflammation"},{"issue":"8","key":"10.1016\/j.autrev.2026.104033_bb1125","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1002\/eji.200425050","article-title":"Frontline: Epitope recognition on the myelin\/oligodendrocyte glycoprotein differentially influences disease phenotype and antibody effector functions in autoimmune demyelination","volume":"34","author":"B\u00fcdingen","year":"2004","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2026.104033_bb1130","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.755900","article-title":"A spontaneous model of experimental autoimmune encephalomyelitis provides evidence of MOG-Specific B cell recruitment and clonal expansion","volume":"13","author":"Salvador","year":"2022","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104033_bb1135","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1093\/brain\/awab231","article-title":"MOG autoantibodies trigger a tightly-controlled FcR and BTK-driven microglia proliferative response","volume":"144","author":"Pellerin","year":"2021","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.autrev.2026.104033_bb1220","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1007\/s00415-017-8635-4","article-title":"Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study","volume":"264","author":"Mariotto","year":"2017","journal-title":"J Neurol"},{"issue":"Pt 8","key":"10.1016\/j.autrev.2026.104033_bb1140","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1093\/brain\/awu142","article-title":"Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes","volume":"137","author":"Carvajal-Gonzalez","year":"2014","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.autrev.2026.104033_bb1145","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/ana.25832","article-title":"Glycine receptor autoantibodies impair receptor function and induce motor dysfunction","volume":"88","author":"Rauschenberger","year":"2020","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104033_bb1150","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/nan.12666","article-title":"Systemic delivery of human GlyR IgG antibody induces GlyR internalization into motor neurons of brainstem and spinal cord with motor dysfunction in mice","volume":"47","author":"Carvajal-Gonzalez","year":"2021","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104033_bb1155","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200364","article-title":"Impaired presynaptic function contributes significantly to the pathology of glycine receptor autoantibodies","volume":"12","author":"Wiessler","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"11","key":"10.1016\/j.autrev.2026.104033_bb1160","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1093\/brain\/awz297","article-title":"Glycine receptor autoantibodies disrupt inhibitory neurotransmission","volume":"142","author":"Crisp","year":"2019","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.autrev.2026.104033_bb1165","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S1474-4422(13)70299-0","article-title":"Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies","volume":"13","author":"Petit-Pedrol","year":"2014","journal-title":"Lancet Neurol"},{"issue":"24","key":"10.1016\/j.autrev.2026.104033_bb1170","doi-asserted-by":"crossref","first-page":"8151","DOI":"10.1523\/JNEUROSCI.4415-13.2014","article-title":"Identification and characterization of GABA(A) receptor autoantibodies in autoimmune encephalitis","volume":"34","author":"Ohkawa","year":"2014","journal-title":"J Neurosci"},{"issue":"11","key":"10.1016\/j.autrev.2026.104033_bb1175","article-title":"Encephalitis patient-derived monoclonal GABAA receptor antibodies cause epileptic seizures","volume":"218","author":"Kreye","year":"2021","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.autrev.2026.104033_bb1185","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.3390\/ijms23073707","article-title":"GABA(A) receptor autoantibodies decrease GABAergic synaptic transmission in the hippocampal CA3 network","volume":"23","author":"Menke","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.autrev.2026.104033_bb1190","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1916337118","article-title":"Cross-reactivity of a pathogenic autoantibody to a tumor antigen in GABA(A) receptor encephalitis","volume":"118","author":"Brandle","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb1195","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1474-4422(09)70324-2","article-title":"Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen","volume":"9","author":"Lancaster","year":"2010","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104033_bb1200","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/epi4.12067","article-title":"Pathogenic potential of antibodies to the GABA(B) receptor","volume":"2","author":"Nibber","year":"2017","journal-title":"Epilepsia Open"},{"issue":"2","key":"10.1016\/j.autrev.2026.104033_bb1205","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.expneurol.2007.01.012","article-title":"A human anti-neuronal autoantibody against GABA B receptor induces experimental autoimmune agrypnia","volume":"204","author":"Frisullo","year":"2007","journal-title":"Exp Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb1210","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.neuron.2018.07.048","article-title":"Human autoantibodies against the AMPA receptor subunit GluA2 induce receptor reorganization and memory dysfunction","volume":"100","author":"Haselmann","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.autrev.2026.104033_bb1215","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.psyneuen.2014.01.005","article-title":"Glutamate receptor antibodies directed against AMPA receptors subunit 3 peptide B (GluR3B) can be produced in DBA\/2J mice, lower seizure threshold and induce abnormal behavior","volume":"42","author":"Ganor","year":"2014","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb1225","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12974-016-0689-1","article-title":"Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome","volume":"13","author":"Sabater","year":"2016","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.autrev.2026.104033_bb1230","article-title":"Patients\u2019 IgLON5 autoantibodies interfere with IgLON5-protein interactions","volume":"14","author":"Landa","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104033_bb1235","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/ana.25857","article-title":"Effects of IgLON5 antibodies on neuronal cytoskeleton: a link between autoimmunity and neurodegeneration","volume":"88","author":"Landa","year":"2020","journal-title":"Ann Neurol"},{"issue":"14","key":"10.1016\/j.autrev.2026.104033_bb1240","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1212\/WNL.0000000000003796","article-title":"DPPX antibody-associated encephalitis: Main syndrome and antibody effects","volume":"88","author":"Hara","year":"2017","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.autrev.2026.104033_bb1245","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000001907","article-title":"Anti-DPPX encephalitis: pathogenic effects of antibodies on gut and brain neurons","volume":"85","author":"Piepgras","year":"2015","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.autrev.2026.104033_bb1250","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.4049\/jimmunol.1102592","article-title":"Brain human monoclonal autoantibody from sydenham chorea targets dopaminergic neurons in transgenic mice and signals dopamine D2 receptor: implications in human disease","volume":"191","author":"Cox","year":"2013","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb1255","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s40478-016-0397-1","article-title":"Dopamine-2 receptor extracellular N-terminus regulates receptor surface availability and is the target of human pathogenic antibodies from children with movement and psychiatric disorders","volume":"4","author":"Sinmaz","year":"2016","journal-title":"Acta Neuropathol Commun"},{"issue":"22","key":"10.1016\/j.autrev.2026.104033_bb1260","doi-asserted-by":"crossref","first-page":"e1964","DOI":"10.1212\/WNL.0000000000005614","article-title":"Encephalitis with mGluR5 antibodies: Symptoms and antibody effects","volume":"90","author":"Spatola","year":"2018","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.autrev.2026.104033_bb1265","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/ana.10451","article-title":"Mechanisms underlying cerebellar motor deficits due to mGluR1-autoantibodies","volume":"53","author":"Coesmans","year":"2003","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb1270","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/ana.26098","article-title":"Encephalitis with autoantibodies against the Glutamate Kainate receptors GluK2","volume":"90","author":"Landa","year":"2021","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb1275","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000916","article-title":"Seizure-related 6 homolog like 2 autoimmunity: neurologic syndrome and antibody effects","volume":"8","author":"Landa","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb1280","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s12974-025-03637-7","article-title":"Sez6L2 autoimmunity induces cerebellar ataxia in mice","volume":"22","author":"Reyes-Sepulveda","year":"2025","journal-title":"J Neuroinflammation"},{"issue":"12","key":"10.1016\/j.autrev.2026.104033_bb0525","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1038\/s41594-024-01386-4","article-title":"Structural and functional mechanisms of anti-NMDAR autoimmune encephalitis","volume":"31","author":"Michalski","year":"2024","journal-title":"Nat Struct Mol Biol"},{"issue":"Pt 10","key":"10.1016\/j.autrev.2026.104033_bb0540","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1093\/brain\/aww208","article-title":"Human cerebrospinal fluid monoclonal N-methyl-D-aspartate receptor autoantibodies are sufficient for encephalitis pathogenesis","volume":"139","author":"Kreye","year":"2016","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.autrev.2026.104033_bb0545","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.25460","article-title":"N-methyl-D-aspartate receptor dysfunction by unmutated human antibodies against the NR1 subunit","volume":"85","author":"Wenke","year":"2019","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104033_bb0560","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1093\/brain\/awae236","article-title":"Autoimmune \u2018secondary synaptopathies\u2019: Do NMDAR antibodies cause a primary extra-synaptopathy?","volume":"147","author":"Zhao","year":"2024","journal-title":"Brain"},{"issue":"35","key":"10.1016\/j.autrev.2026.104033_bb0600","doi-asserted-by":"crossref","first-page":"12650","DOI":"10.1523\/JNEUROSCI.2455-11.2011","article-title":"NMDA receptor signaling in oligodendrocyte progenitors is not required for oligodendrogenesis and myelination","volume":"31","author":"De Biase","year":"2011","journal-title":"J Neurosci"},{"issue":"2","key":"10.1016\/j.autrev.2026.104033_bb0665","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00018-019-03269-0","article-title":"Insights into the mechanisms of epilepsy from structural biology of LGI1-ADAM22","volume":"77","author":"Yamagata","year":"2020","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0670","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/s41467-018-03947-w","article-title":"Structural basis of epilepsy-related ligand-receptor complex LGI1-ADAM22","volume":"9","author":"Yamagata","year":"2018","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.autrev.2026.104033_bb0695","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200284","article-title":"LGI1 autoantibodies enhance synaptic transmission by Presynaptic K(v)1 loss and increased action potential broadening","volume":"11","author":"Ritzau-Jost","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"8","key":"10.1016\/j.autrev.2026.104033_bb0725","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1093\/brain\/awae129","article-title":"Peripherally-derived LGI1-reactive monoclonal antibodies cause epileptic seizures in vivo","volume":"147","author":"Upadhya","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2026.104033_bb0760","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3389\/fncel.2015.00265","article-title":"Inhibitory axons are targeted in hippocampal cell culture by anti-Caspr2 autoantibodies associated with limbic encephalitis","volume":"9","author":"Pinatel","year":"2015","journal-title":"Front Cell Neurosci"},{"issue":"12","key":"10.1016\/j.autrev.2026.104033_bb0820","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamem.2021.183772","article-title":"Pathogenic antibodies to AQP4: neuromyelitis optica spectrum disorder (NMOSD)","volume":"1863","author":"Wright","year":"2021","journal-title":"Biochim Biophys Acta Biomembr"},{"issue":"19","key":"10.1016\/j.autrev.2026.104033_bb0830","doi-asserted-by":"crossref","first-page":"12123","DOI":"10.1074\/jbc.M115.647149","article-title":"Mutagenesis of the aquaporin 4 extracellular domains defines restricted binding patterns of pathogenic neuromyelitis optica IgG","volume":"290","author":"Owens","year":"2015","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0875","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.molcel.2016.05.016","article-title":"Molecular basis of assembly and activation of complement component C1 in complex with immunoglobulin G1 and antigen","volume":"63","author":"Wang","year":"2016","journal-title":"Mol Cell"},{"issue":"13","key":"10.1016\/j.autrev.2026.104033_bb0895","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/glia.20855","article-title":"Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies","volume":"57","author":"Nicchia","year":"2009","journal-title":"Glia"},{"issue":"6","key":"10.1016\/j.autrev.2026.104033_bb0900","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1002\/jnr.22822","article-title":"Neuromyelitis Optica Immunoglobulin G present in sera from neuromyelitis optica patients affects aquaporin-4 expression and water permeability of the astrocyte plasma membrane","volume":"90","author":"Melamud","year":"2012","journal-title":"J Neurosci Res"},{"issue":"12","key":"10.1016\/j.autrev.2026.104033_bb0905","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/glia.22417","article-title":"Neuromyelitis optica IgG does not alter aquaporin-4 water permeability, plasma membrane M1\/M23 isoform content, or supramolecular assembly","volume":"60","author":"Rossi","year":"2012","journal-title":"Glia"},{"issue":"8","key":"10.1016\/j.autrev.2026.104033_bb0910","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adq7560","article-title":"Structural basis of aquaporin-4 autoantibody binding in neuromyelitis optica","volume":"11","author":"Gupta","year":"2025","journal-title":"Sci Adv"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb0930","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/bpa.12793","article-title":"Experimental animal models of aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders: progress and shortcomings","volume":"30","author":"Duan","year":"2020","journal-title":"Brain Pathol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104033_bb1040","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/brain\/awaa102","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study","volume":"143","author":"Takai","year":"2020","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.autrev.2026.104033_bb1045","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","volume":"139","author":"H\u00f6ftberger","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104033_bb1065","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001027","article-title":"Differential binding of autoantibodies to MOG isoforms in inflammatory demyelinating diseases","volume":"8","author":"Schanda","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"8","key":"10.1016\/j.autrev.2026.104033_bb1070","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/brain\/awab105","article-title":"Features of MOG required for recognition by patients with MOG antibody-associated disorders","volume":"144","author":"Macrini","year":"2021","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb1075","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40478-019-0786-3","article-title":"Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination","volume":"7","author":"Tea","year":"2019","journal-title":"Acta Neuropathol Commun"},{"issue":"6","key":"10.1016\/j.autrev.2026.104033_bb1080","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/jnnp-2023-332851","article-title":"The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease","volume":"95","author":"Liyanage","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"10.1016\/j.autrev.2026.104033_bb1085","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1136\/jnnp-2024-335579","article-title":"MOG antibody non-P42 epitope is associated with a higher risk of relapse in paediatric MOGAD","volume":"96","author":"El Hajj","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"10.1016\/j.autrev.2026.104033_bb1090","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028977","article-title":"Experimental autoimmune encephalomyelitis (EAE) as animal models of multiple sclerosis (MS)","volume":"8","author":"Glatigny","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"9","key":"10.1016\/j.autrev.2026.104033_bb1180","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1916337118","article-title":"Cross-reactivity of a pathogenic autoantibody to a tumor antigen in GABA(A) receptor encephalitis","volume":"118","author":"Brandle","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.autrev.2026.104033_bb1285","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1007\/s10875-021-01128-x","article-title":"Anti-voltage-gated potassium channel (VGKC) antibodies and acquired neuromyotonia in patients with immune dysregulation, polyendocrinopathy, enteropathy X-lined (IPEX) syndrome","volume":"41","author":"Moseley","year":"2021","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.autrev.2026.104033_bb1290","article-title":"GAD antibody-associated limbic encephalitis in a young woman with APECED","volume":"2017","author":"Kopczak","year":"2017","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"3","key":"10.1016\/j.autrev.2026.104033_bb1295","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41576-023-00656-z","article-title":"Inborn errors of immunity: an expanding universe of disease and genetic architecture","volume":"25","author":"Akalu","year":"2024","journal-title":"Nat Rev Genet"},{"issue":"7","key":"10.1016\/j.autrev.2026.104033_bb1300","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s10875-022-01289-3","article-title":"Human inborn errors of immunity: 2022 update on the classification from the international union of immunological societies expert committee","volume":"42","author":"Tangye","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.autrev.2026.104033_bb1305","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2019.100015","article-title":"Identifying the culprits in neurological autoimmune diseases","volume":"2","author":"Acosta-Ampudia","year":"2019","journal-title":"J Transl Autoimmun"},{"issue":"2","key":"10.1016\/j.autrev.2026.104033_bb1310","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ana.24860","article-title":"Anti-LGI1 encephalitis is associated with unique HLA subtypes","volume":"81","author":"Kim","year":"2017","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104033_bb1315","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000974","article-title":"Clinical and prognostic value of immunogenetic characteristics in Anti-LGI1 encephalitis","volume":"8","author":"Muniz-Castrillo","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"10.1016\/j.autrev.2026.104033_bb1320","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000605","article-title":"HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease","volume":"6","author":"Gaig","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7","key":"10.1016\/j.autrev.2026.104033_bb1325","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1093\/brain\/awae048","article-title":"HLA-DQB1*05 subtypes and not DRB1*10:01 mediates risk in anti-IgLON5 disease","volume":"147","author":"Yogeshwar","year":"2024","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.autrev.2026.104033_bb1330","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/brain\/awae349","article-title":"Novel risk loci in LGI1-antibody encephalitis: genome-wide association study discovery and validation cohorts","volume":"148","author":"Binks","year":"2025","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb1335","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/cen3.12078","article-title":"Genetic studies of multiple sclerosis and neuromyelitis optica: current status in European, African American and Asian populations","volume":"5","author":"Isobe","year":"2014","journal-title":"Clin Exp Neuroimmunol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104033_bb1340","article-title":"Contribution of germline and somatic mutations to risk of neuromyelitis optica spectrum disorder","volume":"5","author":"Yata","year":"2025","journal-title":"Cell Genom"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb1345","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1038\/s41467-018-04332-3","article-title":"A whole-genome sequence study identifies genetic risk factors for neuromyelitis optica","volume":"9","author":"Estrada","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2026.104033_bb1350","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1423149","article-title":"HLA and KIR genetic association and NK cells in anti-NMDAR encephalitis","volume":"15","author":"Peris Sempere","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104033_bb1355","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.brainresbull.2017.05.004","article-title":"MicroRNA-129-5p inhibits the development of autoimmune encephalomyelitis-related epilepsy by targeting HMGB1 through the TLR4\/NF-kB signaling pathway","volume":"132","author":"Liu","year":"2017","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.autrev.2026.104033_bb1360","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.3389\/fimmu.2019.03094","article-title":"Environmental exposures and autoimmune diseases: contribution of gut microbiome","volume":"10","author":"Khan","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104033_bb1365","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2025.101956","article-title":"The pathogenesis of neurological immune-related adverse events following immune checkpoint inhibitor therapy","volume":"78","author":"Lerch","year":"2025","journal-title":"Semin Immunol"},{"key":"10.1016\/j.autrev.2026.104033_bb1370","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.120044","article-title":"Exposure to TNF inhibitors is rare at MOGAD presentation","volume":"432","author":"Redenbaugh","year":"2022","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb1375","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ana.23651","article-title":"Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter","volume":"72","author":"Varrin-Doyer","year":"2012","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104033_bb1380","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/ana.24718","article-title":"Gut microbiome analysis in neuromyelitis optica reveals overabundance of Clostridium perfringens","volume":"80","author":"Cree","year":"2016","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb1385","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000907","article-title":"Clostridium bolteae is elevated in neuromyelitis optica spectrum disorder in India and shares sequence similarity with AQP4","volume":"8","author":"Pandit","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2026.104033_bb1390","article-title":"Perturbations in gut microbiota composition in patients with autoimmune neurological diseases: a systematic review and meta-analysis","volume":"16","author":"Deng","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104033_bb1395","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117394","article-title":"Autoimmune encephalitis after Japanese encephalitis in children: a prospective study","volume":"424","author":"Liu","year":"2021","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb1400","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12883-017-0858-6","article-title":"Anti-MOG antibody-positive ADEM following infectious mononucleosis due to a primary EBV infection: a case report","volume":"17","author":"Nakamura","year":"2017","journal-title":"BMC Neurol"},{"key":"10.1016\/j.autrev.2026.104033_bb1405","doi-asserted-by":"crossref","DOI":"10.1177\/2329048X20942442","article-title":"Postinfectious acute disseminated encephalomyelitis associated with antimyelin oligodendrocyte glycoprotein antibody","volume":"7","author":"Sato","year":"2020","journal-title":"Child Neurol Open"},{"key":"10.1016\/j.autrev.2026.104033_bb1410","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.msard.2017.07.023","article-title":"A case of MOG antibody-positive bilateral optic neuritis and meningoganglionitis following a genital herpes simplex virus infection","volume":"17","author":"Nakamura","year":"2017","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.autrev.2026.104033_bb1415","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3988\/jcn.2018.14.4.598","article-title":"The relationship between anti-myelin oligodendrocyte glycoprotein antibody-associated disease and the rubella virus","volume":"14","author":"Choi","year":"2018","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.autrev.2026.104033_bb1420","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.769653","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease and varicella zoster virus infection - frequency of an association","volume":"12","author":"Di Pauli","year":"2021","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104033_bb1425","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/ana.23689","article-title":"N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis","volume":"72","author":"Pruss","year":"2012","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104033_bb1430","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000529","article-title":"Mouse model of anti-NMDA receptor post-herpes simplex encephalitis","volume":"6","author":"Linnoila","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.autrev.2026.104033_bb1435","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000073","article-title":"GABAA receptor and LGI1 antibody encephalitis in a patient with thymoma","volume":"2","author":"Simabukuro","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"10.1016\/j.autrev.2026.104033_bb1440","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ana.25173","article-title":"N-methyl-D-aspartate receptor antibody production from germinal center reactions: therapeutic implications","volume":"83","author":"Makuch","year":"2018","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb1445","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1038\/s41598-020-60438-z","article-title":"Antibody transcytosis across brain endothelial-like cells occurs nonspecifically and independent of FcRn","volume":"10","author":"Ruano-Salguero","year":"2020","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.autrev.2026.104033_bb1450","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.it.2012.07.004","article-title":"Capture, crawl, cross: the T cell code to breach the blood-brain barriers","volume":"33","author":"Engelhardt","year":"2012","journal-title":"Trends Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb1455","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/cns.13569","article-title":"Peripheral inflammation and blood-brain barrier disruption: effects and mechanisms","volume":"27","author":"Huang","year":"2021","journal-title":"CNS Neurosci Ther"},{"issue":"5","key":"10.1016\/j.autrev.2026.104033_bb1460","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000841","article-title":"Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology","volume":"7","author":"Fujihara","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb1465","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nn.4193","article-title":"Oligodendrocyte death results in immune-mediated CNS demyelination","volume":"19","author":"Traka","year":"2016","journal-title":"Nat Neurosci"},{"issue":"10","key":"10.1016\/j.autrev.2026.104033_bb1470","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/s41593-018-0227-9","article-title":"CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature","volume":"21","author":"Louveau","year":"2018","journal-title":"Nat Neurosci"},{"issue":"10","key":"10.1016\/j.autrev.2026.104033_bb1475","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.4049\/jimmunol.169.10.5415","article-title":"Transfer of central nervous system autoantigens and presentation in secondary lymphoid organs","volume":"169","author":"Vos","year":"2002","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104033_bb1480","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1093\/brain\/awac088","article-title":"Cervical lymph nodes and ovarian teratomas as germinal centres in NMDA receptor-antibody encephalitis","volume":"145","author":"Al-Diwani","year":"2022","journal-title":"Brain"},{"issue":"24","key":"10.1016\/j.autrev.2026.104033_bb1485","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2121804119","article-title":"Rituximab abrogates aquaporin-4-specific germinal center activity in patients with neuromyelitis optica spectrum disorders","volume":"119","author":"Damato","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.autrev.2026.104033_bb1490","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2311049121","article-title":"Ultrahigh frequencies of peripherally matured LGI1- and CASPR2-reactive B cells characterize the cerebrospinal fluid in autoimmune encephalitis","volume":"121","author":"Theorell","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2026.104033_bb1495","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/B978-0-12-823912-4.00015-3","article-title":"Overview of treatment strategies in paraneoplastic neurological syndromes","volume":"200","author":"Kerstens","year":"2024","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.autrev.2026.104033_bb1500","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.120042","article-title":"Intrathecal methotrexate - another tool for the treatment of refractory autoimmune encephalitis - single institution cohort and literature review","volume":"431","author":"Eaton","year":"2021","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb1505","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/jnnp-2022-330086","article-title":"Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis","volume":"94","author":"Spagni","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.autrev.2026.104033_bb1510","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104033_bb1515","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2025.e41747","article-title":"Efficacy of rituximab as second-line therapy for autoimmune encephalitis: a systematic review and meta-analysis","volume":"11","author":"Zhang","year":"2025","journal-title":"Heliyon"},{"issue":"4","key":"10.1016\/j.autrev.2026.104033_bb1520","article-title":"Rituximab use for relapse prevention in anti-NMDAR antibody-mediated encephalitis: a multicenter cohort study","volume":"12","author":"Seery","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"12","key":"10.1016\/j.autrev.2026.104033_bb1645","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1111\/cns.14416","article-title":"Ofatumumab for the treatment of refractory anti-LGI1 encephalitis with long-term poor blood glucose control in type 1 diabetes","volume":"29","author":"Chen","year":"2023","journal-title":"CNS Neurosci Ther"},{"issue":"3","key":"10.1016\/j.autrev.2026.104033_bb1650","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s10072-024-07876-z","article-title":"Efficacy of ofatumumab combined with corticosteroids in the treatment of autoimmune encephalitis: a 6-month cohort study","volume":"46","author":"She","year":"2025","journal-title":"Neurol Sci"},{"issue":"10206","key":"10.1016\/j.autrev.2026.104033_bb1530","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.autrev.2026.104033_bb1655","article-title":"A Phase-2B double-blind randomized international prospective trial of inebilizumab in NMDAR encephalitis: the ExTINGUISH trial","volume":"1","author":"Wong","year":"2025","journal-title":"Neurol Open Access"},{"key":"10.1016\/j.autrev.2026.104033_bb1535","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105859","article-title":"Efficacy of tocilizumab in highly relapsing MOGAD with an inadequate response to intravenous immunoglobulin therapy: a case series","volume":"91","author":"Kang","year":"2024","journal-title":"Mult Scler Relat Disord"},{"issue":"22","key":"10.1016\/j.autrev.2026.104033_bb1540","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.autrev.2026.104033_bb1660","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamaneurol.2013.143","article-title":"Successful treatment of anti-Caspr2 syndrome by interleukin 6 receptor blockade through tocilizumab","volume":"70","author":"Krogias","year":"2013","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb1665","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s13311-020-00921-7","article-title":"Teratoma removal, steroid, IVIG, Rituximab and Tocilizumab (T-SIRT) in Anti-NMDAR encephalitis","volume":"18","author":"Lee","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"4","key":"10.1016\/j.autrev.2026.104033_bb1670","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s13311-016-0442-6","article-title":"Tocilizumab in autoimmune encephalitis refractory to rituximab: an institutional cohort study","volume":"13","author":"Lee","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.autrev.2026.104033_bb1675","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105062","article-title":"Tocilizumab treatment in neuromyelitis optica spectrum disorders: updated meta-analysis of efficacy and safety","volume":"80","author":"Wang","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2026.104033_bb1680","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1437913","article-title":"Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO)","volume":"15","author":"Lee","year":"2024","journal-title":"Front Neurol"},{"key":"10.1016\/j.autrev.2026.104033_bb1545","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fneur.2015.00167","article-title":"Treating a GAD65 antibody-associated limbic encephalitis with basiliximab: a case study","volume":"6","author":"Widman","year":"2015","journal-title":"Front Neurol"},{"key":"10.1016\/j.autrev.2026.104033_bb1550","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jneuroim.2016.09.001","article-title":"New feasible treatment for refractory autoimmune encephalitis: low-dose interleukin-2","volume":"299","author":"Lim","year":"2016","journal-title":"J Neuroimmunol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104033_bb1555","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in Aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"93","author":"Pittock","year":"2023","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1016\/j.autrev.2026.104033_bb1560","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104033_bb1685","article-title":"Real-life study to assess effectiveness and safety of eculizumab in patients with neuromyelitis optica spectrum disorders in France: protocol for ECUP4, an observational study","volume":"14","author":"Marignier","year":"2023","journal-title":"Front Neurol"},{"key":"10.1016\/j.autrev.2026.104033_bb1690","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.602102","article-title":"Case report: daratumumab in a patient with severe refractory Anti-NMDA receptor encephalitis","volume":"11","author":"Ratuszny","year":"2020","journal-title":"Front Neurol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104033_bb1695","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00415-019-09585-6","article-title":"Daratumumab treatment for therapy-refractory anti-CASPR2 encephalitis","volume":"267","author":"Scheibe","year":"2020","journal-title":"J Neurol"},{"issue":"23_Supplement_2","key":"10.1016\/j.autrev.2026.104033_bb1565","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1212\/01.wnl.0000903336.22071.b3","article-title":"The first randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy and safety of an FcRn Inhibitor, Rozanolixizumab, in patients with leucine-rich gliomainactivated 1 autoimmune encephalitis","volume":"99","author":"Dubey","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2026.104033_bb1570","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2025.123597","article-title":"Multicenter experience with Efgartigimod in the treatment of anti-NMDAR encephalitis compared with IVIG and SPA-IA during acute attacks","volume":"371","author":"Liu","year":"2025","journal-title":"Life Sci"},{"issue":"5","key":"10.1016\/j.autrev.2026.104033_bb1575","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s10072-024-07843-8","article-title":"Efgartigimod treatment for therapy-refractory autoimmune encephalitis with coexistent NMDAR and LGI1 antibodies: a case report and literature review","volume":"46","author":"Xu","year":"2025","journal-title":"Neurol Sci"},{"key":"10.1016\/j.autrev.2026.104033_bb1580","article-title":"Case report: Rapid symptom relief in autoimmune encephalitis with efgartigimod: a three-patient case series","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb1585","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1186\/s13063-020-04516-7","article-title":"Generate-Boost: study protocol for a prospective, multicenter, randomized controlled, double-blinded phase II trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitis","volume":"21","author":"Wickel","year":"2020","journal-title":"Trials"},{"issue":"4","key":"10.1016\/j.autrev.2026.104033_bb1590","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/WNL.0000000000003536","article-title":"Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis","volume":"88","author":"Scheibe","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb1700","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-024523","article-title":"Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial","volume":"9","author":"Kohler","year":"2019","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.autrev.2026.104033_bb1595","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1111\/epi.16848","article-title":"Tofacitinib treatment for refractory autoimmune encephalitis","volume":"62","author":"Jang","year":"2021","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.autrev.2026.104033_bb1705","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000328","article-title":"Ruxolitinib treatment in a patient with neuromyelitis optica: a case report","volume":"4","author":"Hodecker","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb1600","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.1038\/s41467-025-60628-1","article-title":"Monoclonal humanized monovalent antibody blocking therapy for anti-NMDA receptor encephalitis","volume":"16","author":"Kanno","year":"2025","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.autrev.2026.104033_bb1605","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1093\/brain\/awaa195","article-title":"Allosteric modulation of NMDA receptors prevents the antibody effects of patients with anti-NMDAR encephalitis","volume":"143","author":"Mannara","year":"2020","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.autrev.2026.104033_bb1610","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200261","article-title":"Positive allosteric modulation of NMDARs prevents the altered surface dynamics caused by patients\u2019 antibodies","volume":"11","author":"Maudes","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"10.1016\/j.autrev.2026.104033_bb1615","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.5989","article-title":"Late relapse after autologous hematopoietic stem cell transplantation in AQP4-IgG-positive NMOSD","volume":"8","author":"Vorasoot","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.autrev.2026.104033_bb1620","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jocn.2022.08.020","article-title":"Autologous hematopoietic stem cell transplantation in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis","volume":"105","author":"Nabizadeh","year":"2022","journal-title":"J Clin Neurosci"},{"issue":"4\u20135","key":"10.1016\/j.autrev.2026.104033_bb1625","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1177\/13524585231213792","article-title":"An aggressive form of MOGAD treated with aHSCT: a case report","volume":"30","author":"Sbragia","year":"2024","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2026.104033_bb1710","doi-asserted-by":"crossref","DOI":"10.1177\/09636897221110876","article-title":"Human umbilical cord mesenchymal stem cells for severe neurological sequelae due to Anti-N-Methyl-d-aspartate receptor encephalitis: first case report","volume":"31","author":"Nguyen Thanh","year":"2022","journal-title":"Cell Transplant"},{"issue":"1","key":"10.1016\/j.autrev.2026.104033_bb1630","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"10.1016\/j.autrev.2026.104033_bb1635","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1474-4422(24)00140-6","article-title":"B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases","volume":"23","author":"Haghikia","year":"2024","journal-title":"Lancet Neurol"},{"issue":"23","key":"10.1016\/j.autrev.2026.104033_bb1640","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1016\/j.cell.2023.10.001","article-title":"Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells","volume":"186","author":"Reincke","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2026.104033_bb1525","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1352779","article-title":"Case report: transition from anti-CD20 therapy to inebilizumab for 14 cases of neuromyelitis optica spectrum disorder","volume":"15","author":"Osborne","year":"2024","journal-title":"Front Neurol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T19:14:59Z","timestamp":1776194099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226000479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":343,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1568997226000479"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104033","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathogenic mechanisms of action of autoantibody-mediated central nervous system disorders targeting neuroglial surface antigens","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104033"}}